Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Newtopia Inks Aetna Contract for Metabolic Syndrome Personalized Med Program

Newtopia Inks Aetna Contract for Metabolic Syndrome Personalized Med Program

Feb 18, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Following a pilot study, Newtopia has signed a contract to provide Aetna's customers with a personalized health program that utilizes genetic testing and behavioral science targeted at those with metabolic syndrome.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

What's Popular?

In Business News

  1. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  2. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  3. Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

  4. Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

  5. Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.